Literature DB >> 7925582

Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis.

O H Brekke1, T E Michaelsen, A Aase, R H Sandin, I Sandlie.   

Abstract

In this report we describe the construction of anti-5-iodo-4-hydroxy-3-nitrophenacetyl (NIP) mouse/human immunoglobulin (Ig) G4 chimeric molecules with altered amino acid residues in the CH2 domain. Three mutants are described. Gln-268 is substituted by His in gamma 4 Q268H, Ser-331 is substituted by Pro in gamma 4 S331P, and in gamma 4 Q268H/S331P both residues are substituted. The ability of the mutant molecules to induce complement-mediated cell lysis (CML) and phagocytosis by Fc gamma RII- and Fc gamma RIII-bearing polymorphonuclear leukocytes (PMN) were measured. In CML, gamma 4 Q268H was inactive, but both gamma 4 S331P and gamma 4 Q268H/S331P were active provided that the antigenic density on the target cells was high. In phagocytosis mediated by PMN, the mutants gamma 4 S331P and gamma 4 Q268H/S331P were both active only when complement was introduced. gamma 4 Q268H was not active in phagocytosis under any conditions. We conclude that His-268 in human IgG molecules does not modulate CML activity or phagocytosis mediated by Fc gamma RII and/or Fc gamma RIII. Pro-331 rescues CML activity in IgG4 molecules when the epitope density on the target cells is high, but does not affect Fc gamma RII/Fc gamma RIII-mediated phagocytosis. In this manner the mutants gamma 4 S331P and gamma 4 Q268H/S331P mimic human IgG2. This could indicate a structural similarity between IgG2 and these mutant molecules that distinguish them from both IgG1 and IgG3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925582     DOI: 10.1002/eji.1830241042

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

2.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

3.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 4.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

5.  Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.

Authors:  Sandra Lightle; Serdar Aykent; Nathan Lacher; Vesselin Mitaksov; Kristine Wells; James Zobel; Theodore Oliphant
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

6.  Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity.

Authors:  Doan C Nguyen; Rashesh Sanghvi; Franco Scinicariello; Joanna Pulit-Penaloza; Nicole Hill; Roberta Attanasio
Journal:  Immunogenetics       Date:  2014-05-09       Impact factor: 2.846

7.  Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation.

Authors:  Yanling Lu; Stephen E Harding; Terje E Michaelsen; Emma Longman; Kenneth G Davis; Alvaro Ortega; J Günter Grossmann; Inger Sandlie; José García de la Torre
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

Review 8.  IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease.

Authors:  Mukul Divatia; Sun A Kim; Jae Y Ro
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

Review 9.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

Review 10.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.